What is KLRS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for KLRS?

P/E (TTM) is n/a and 52-week range is $2.35 to $11.88 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s KLRS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for KLRS?

The company profile lists net income (TTM) near $-50M, EPS (TTM) near $-2.09 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Kalaris Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Berkeley Heights, New Jersey, US, 23.8M shares outstanding, ISIN US4829291065 when available from company profile and filing metadata.

Chartloom

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 20 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Employees

Website

kalaristx.com/

IPO

2020-07-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)